Ashley Chan

Articles by Ashley Chan

$Patients with RS-negative low-risk MDS who were relapsed or refractory to or ineligible for ESAs appeared to experience clinical benefit with imetelstat treatment in a post hoc analysis. | Image credit: fotogurmespb - stock.adobe.com$

Imetelstat Shows Benefit in RS-Negative, Lower-Risk MDS

ByAshley Chan

July 1st 2025

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

Ovarian cancer animation | Image Credit: Nuchjaree - stock.adobe.com

Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial

ByAshley Chan

September 24th 2024

Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.

Ashley Chan

Articles by Ashley Chan

Imetelstat Shows Benefit in RS-Negative, Lower-Risk MDS

Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial

Latest Updated Articles

Trending on AJMC

FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma

IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?

Eliminating Cost Sharing Boosted Follow-Up Colonoscopy Rates

Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD

5 September FDA Approvals That Are Transforming Treatment This Fall